FTL Antibodies 

FTL (Ferritin Light Chain) is a subunit of the ferritin protein complex, which plays a central role in iron storage and regulation within cells. Ferritin consists of both light (FTL) and heavy (FTH) chains, with FTL primarily responsible for the proper assembly and stability of the ferritin complex, as well as the storage of iron in a bioavailable and non-toxic form. Dysregulation of FTL has been linked to various iron-related disorders, including neurodegenerative diseases and anemia.

Content

FTL antibodies are developed to specifically target the Ferritin Light Chain, enabling the detection and study of its expression in different biological contexts. These antibodies are commonly used in immunohistochemistry (IHC), Western blotting, immunoprecipitation (IP), and enzyme-linked immunosorbent assays (ELISA) to assess FTL levels in tissues and cells. They are also used to explore the role of FTL in iron metabolism, neurodegeneration, and conditions where iron homeostasis is disrupted.

Applications

• Iron Metabolism Research: FTL is a key player in iron storage, and FTL antibodies are essential for studying how cells regulate iron availability. These antibodies are used to assess ferritin levels in various tissues, including liver, spleen, and brain, where iron homeostasis is critical for normal function.
• Neurodegenerative Disease Studies: Abnormalities in iron metabolism, including altered ferritin levels, are associated with neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's disease. FTL antibodies are used to study how dysregulated iron storage contributes to oxidative stress and neuronal damage in these diseases, providing insights into potential therapeutic targets.
• Hematological Disorders: Ferritin levels are a critical biomarker for various anemia-related conditions. FTL antibodies are utilized in the diagnosis and study of conditions such as iron-deficiency anemia and hemochromatosis, where iron overload or deficiency disrupts normal hematopoietic function.
• Cancer Research: Altered iron metabolism is frequently observed in cancer cells, which often require high iron levels to support rapid growth. FTL antibodies are used to investigate how cancer cells manipulate ferritin expression and iron storage to meet their metabolic needs, making it a potential target for therapeutic interventions.
• Biomarker Development: FTL antibodies are employed in the development of diagnostic assays to measure ferritin levels as a biomarker for iron-related disorders. These antibodies are critical for clinical applications where accurate quantification of ferritin is needed to assess iron status and guide treatment decisions.

By leveraging FTL antibodies, researchers can gain detailed insights into the regulation of iron homeostasis and its role in both physiological and pathological conditions, advancing the understanding of diseases linked to iron metabolism and exploring new avenues for targeted therapies.